220 related articles for article (PubMed ID: 17876838)
1. Race, biochemical disease recurrence, and prostate-specific antigen doubling time after radical prostatectomy: results from the SEARCH database.
Hamilton RJ; Aronson WJ; Presti JC; Terris MK; Kane CJ; Amling CL; Freedland SJ
Cancer; 2007 Nov; 110(10):2202-9. PubMed ID: 17876838
[TBL] [Abstract][Full Text] [Related]
2. Race and risk of metastases and survival after radical prostatectomy: Results from the SEARCH database.
Freedland SJ; Vidal AC; Howard LE; Terris MK; Cooperberg MR; Amling CL; Kane CJ; Aronson WJ;
Cancer; 2017 Nov; 123(21):4199-4206. PubMed ID: 28654204
[TBL] [Abstract][Full Text] [Related]
3. Race as an outcome predictor after radical prostatectomy: results from the Shared Equal Access Regional Cancer Hospital (SEARCH) database.
Freedland SJ; Amling CL; Dorey F; Kane CJ; Presti JC; Terris MK; Aronson WJ;
Urology; 2002 Oct; 60(4):670-4. PubMed ID: 12385931
[TBL] [Abstract][Full Text] [Related]
4. Race is not an independent predictor of biochemical recurrence after radical prostatectomy in an equal access medical center.
Freedland SJ; Jalkut M; Dorey F; Sutter ME; Aronson WJ
Urology; 2000 Jul; 56(1):87-91. PubMed ID: 10869631
[TBL] [Abstract][Full Text] [Related]
5. Black and White men younger than 50 years of age demonstrate similar outcomes after radical prostatectomy.
Moses KA; Chen LY; Sjoberg DD; Bernstein M; Touijer KA
BMC Urol; 2014 Dec; 14():98. PubMed ID: 25495177
[TBL] [Abstract][Full Text] [Related]
6. Preoperative PSA velocity and doubling time do not predict adverse pathologic features or biochemical recurrence after radical prostatectomy.
Freedland SJ; Dorey F; Aronson WJ
Urology; 2001 Mar; 57(3):476-80. PubMed ID: 11248623
[TBL] [Abstract][Full Text] [Related]
7. Obesity as a predictor of adverse outcome across black and white race: results from the Shared Equal Access Regional Cancer Hospital (SEARCH) Database.
Jayachandran J; Bañez LL; Aronson WJ; Terris MK; Presti JC; Amling CL; Kane CJ; Freedland SJ;
Cancer; 2009 Nov; 115(22):5263-71. PubMed ID: 19670453
[TBL] [Abstract][Full Text] [Related]
8. The percentage of prostate needle biopsy cores with carcinoma from the more involved side of the biopsy as a predictor of prostate specific antigen recurrence after radical prostatectomy: results from the Shared Equal Access Regional Cancer Hospital (SEARCH) database.
Freedland SJ; Aronson WJ; Terris MK; Kane CJ; Amling CL; Dorey F; Presti JC
Cancer; 2003 Dec; 98(11):2344-50. PubMed ID: 14635068
[TBL] [Abstract][Full Text] [Related]
9. Exposure to Agent Orange is a significant predictor of prostate-specific antigen (PSA)-based recurrence and a rapid PSA doubling time after radical prostatectomy.
Shah SR; Freedland SJ; Aronson WJ; Kane CJ; Presti JC; Amling CL; Terris MK
BJU Int; 2009 May; 103(9):1168-72. PubMed ID: 19298411
[TBL] [Abstract][Full Text] [Related]
10. Prostate-specific antigen values at the time of prostate cancer diagnosis in African-American men.
Moul JW; Sesterhenn IA; Connelly RR; Douglas T; Srivastava S; Mostofi FK; McLeod DG
JAMA; 1995 Oct; 274(16):1277-81. PubMed ID: 7563532
[TBL] [Abstract][Full Text] [Related]
11. Improved biochemical outcome with adjuvant radiotherapy after radical prostatectomy for prostate cancer with poor pathologic features.
Vargas C; Kestin LL; Weed DW; Krauss D; Vicini FA; Martinez AA
Int J Radiat Oncol Biol Phys; 2005 Mar; 61(3):714-24. PubMed ID: 15708249
[TBL] [Abstract][Full Text] [Related]
12. Does larger tumor volume explain the higher prostate specific antigen levels in black men with prostate cancer--Results from the SEARCH database.
Klaassen Z; Howard L; Terris MK; Aronson WJ; Cooperberg MR; Amling CL; Kane CJ; Freedland SJ
Cancer Epidemiol; 2015 Dec; 39(6):1066-70. PubMed ID: 26452418
[TBL] [Abstract][Full Text] [Related]
13. Clinical stage T1c prostate cancer: pathologic outcomes following radical prostatectomy in black and white men.
Eastham JA; Carver B; Katz J; Kattan MW
Prostate; 2002 Mar; 50(4):236-40. PubMed ID: 11870801
[TBL] [Abstract][Full Text] [Related]
14. What are the factors associated with short prostate specific antigen doubling time after radical prostatectomy? A report from the SEARCH database group.
Teeter AE; Bañez LL; Presti JC; Aronson WJ; Terris MK; Kane CJ; Amling CL; Freedland SJ;
J Urol; 2008 Nov; 180(5):1980-4; discussion 1985. PubMed ID: 18801519
[TBL] [Abstract][Full Text] [Related]
15. Prostate specific antigen kinetics at tumor recurrence after radical prostatectomy do not suggest a worse disease prognosis in black men.
Bissonette EA; Fulmer BR; Petroni GR; Moul JW; Theodorescu D
J Urol; 2001 Oct; 166(4):1328-31; discussion 1331-2. PubMed ID: 11547067
[TBL] [Abstract][Full Text] [Related]
16. Racial differences in serum prostate-specific antigen (PSA) doubling time, histopathological variables and long-term PSA recurrence between African-American and white American men undergoing radical prostatectomy for clinically localized prostate cancer.
Tewari A; Horninger W; Badani KK; Hasan M; Coon S; Crawford ED; Gamito EJ; Wei J; Taub D; Montie J; Porter C; Divine GW; Bartsch G; Menon M
BJU Int; 2005 Jul; 96(1):29-33. PubMed ID: 15963115
[TBL] [Abstract][Full Text] [Related]
17. PSA in the new millennium: a powerful predictor of prostate cancer prognosis and radical prostatectomy outcomes--results from the SEARCH database.
Freedland SJ; Hotaling JM; Fitzsimons NJ; Presti JC; Kane CJ; Terris MK; Aronson WJ; Amling CL
Eur Urol; 2008 Apr; 53(4):758-64; discussion 765-6. PubMed ID: 17868976
[TBL] [Abstract][Full Text] [Related]
18. Multivariate analysis of race and adverse pathologic findings after radical prostatectomy.
Freedland SJ; Dorey F; Aronson WJ
Urology; 2000 Nov; 56(5):807-11. PubMed ID: 11068307
[TBL] [Abstract][Full Text] [Related]
19. Obesity is not associated with aggressive pathologic features or biochemical recurrence after radical prostatectomy.
Tomaszewski JJ; Chen YF; Bertolet M; Ristau BT; Woldemichael E; Nelson JB
Urology; 2013 May; 81(5):992-6. PubMed ID: 23453649
[TBL] [Abstract][Full Text] [Related]
20. Clinical and pathologic outcome after radical prostatectomy for prostate cancer patients with a preoperative Gleason sum of 8 to 10.
Bastian PJ; Gonzalgo ML; Aronson WJ; Terris MK; Kane CJ; Amling CL; Presti JC; Mangold LA; Humphreys E; Epstein JI; Partin AW; Freedland SJ
Cancer; 2006 Sep; 107(6):1265-72. PubMed ID: 16900523
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
